We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Portage Biotech Inc (PRTG) NPV

Sell:$6.70 Buy:$7.14 Change: $0.19 (2.76%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.19 (2.76%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.19 (2.76%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Portage Biotech Inc. is a Canada-based clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers and virus-like particles. Within these five platforms, the Company has 10 products, which is under development with multiple clinical readouts. The Company’s subsidiaries include SalvaRx Limited, iOx Therapeutics Ltd., Saugatuck Therapeutics, Ltd. and Portage Developmental Services.

Contact details

47 Avenue Rd Suite 200
M5R 2G3
+1 (416) 9291806

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$95.95 million
Shares in issue:
13.35 million
Virgin Islands
US dollar

Key personnel

  • Gregory Bailey
    Chairman of the Board
  • Ian Walters
    Chief Executive Officer, Director
  • Allan Shaw
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.